Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03127774 · ClinicalTrials.gov registry record · Phase 2
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
A Phase 2 study of Peritoneal Carcinomatosis and Adrenocortical Carcinoma, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03127774: Recruiting Phase 2 study of Peritoneal Carcinomatosis and Adrenocortical Carcinoma, sponsored by Columbia University.
NCT03127774 is a Phase 2 study of Peritoneal Carcinomatosis and Adrenocortical Carcinoma that is actively recruiting participants, run by Columbia University. The registered enrollment target is 30 participants, below the 58-participant average among 14 other Peritoneal Carcinomatosis trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03127774, a Phase 2 study of Peritoneal Carcinomatosis and Adrenocortical Carcinoma, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Objectives: \- To determine intraperitoneal (IP) progression free survival after optimal debulking and heated intraperitoneal chemotherapy (HIPEC) with cisplatin in patients with IP spread of adrenocortical cancer. \- Determine morbidity of this procedure in this patient population. \- Determine the impact of surgery and HIPEC on quality of life (QOL) and hormone excess. \- Examine patterns of recurrence (local versus systemic). \- Determine overall survival after optimal debulking and HIPEC in patients with IP spread of adrenocortical cancer.
Primary Outcome
The length of time after optimal debulking and heated intraperitoneal chemotherapy that a patient lives before there is clinical evidence of recurrent adrenocortical cancer.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Sodium thiosulfate
- PROCEDURE Cytoreductive surgery
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-09-22 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT03127774 shows while recruiting
NCT03127774 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 58-participant average among 14 other Peritoneal Carcinomatosis trials with a reported enrollment target (48% lower).
The record links to 2 conditions, with Peritoneal Carcinomatosis appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT03127774 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03127774 about?
NCT03127774 is a clinical study titled "Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma". Objectives: \- To determine intraperitoneal (IP) progression free survival after optimal debulking and heated intraperitoneal chemotherapy (HIPEC) with cisplatin in patients with IP spread of adrenocortical cancer. \- Determine morbidity of this procedure in this patient population. \- Determine ...
What is the current status of trial NCT03127774?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2017-09-22. Estimated completion is 2025-12.
What conditions does trial NCT03127774 study?
This clinical trial studies the following conditions: Peritoneal Carcinomatosis, Adrenocortical Carcinoma.
What interventions are being tested in trial NCT03127774?
The interventions under investigation include: Cisplatin (DRUG), Sodium thiosulfate (DRUG), Cytoreductive surgery (PROCEDURE).
Who is sponsoring clinical trial NCT03127774?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03127774 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peritoneal Carcinomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03127774's enrollment target sits among peer trials
30 7th of 14 higher than 7 of 14 other Peritoneal Carcinomatosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peritoneal Carcinomatosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
RECRUITING · Phase 2
-
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RECRUITING · Phase 2
-
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI